Detailed description page of THPdb

Details of Th1146 which contains 3 entries.

Entry 1
(1) Primary information
ID 1641
ThPP ID Th1146
Therapeutic Peptide/Protein Name Lucinactant
Sequence KLLLLKLLLLKLLLLKLLLLK view full sequnce in fasta
Functional Classification Ib
Molecular Weight 2470.2
Chemical Formula C126H238N26O22
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description A new synthetic peptide containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). It specifically mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine,Â DPPCÂ and palmitoyloleoyl phosphatidylglycerol,POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.Â FDAÂ approved it on March 6, 2012.
Indication/Disease Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Pharmacodynamics Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.
Mechanism of Action Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
Toxicity Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Pulmonary surfactants
Patents Number US5407914
Date of Issue 03/06/12
Date of Expiry 11/07/13
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name Surfaxin
Company Discovery Laboratories, Inc.
Brand Discription ItÂ is a sterile, non-pyrogenic pulmonaryÂ surfactantÂ intended for intratracheal use only. It is a synthetic formulation consisting of phospholipids, aÂ fatty acid, and sinapultide (KL4peptide), a 21-amino acidÂ hydrophobic synthetic peptide. Surfaxin is a white to off-white opaque gel-like suspension at 2Â° to 8Â°C (36Â° to 46Â°F), which becomes a free-flowing suspension upon warming for 15 minutes in a dry block heater set at 44Â°C (111Â°F). Each mL of Surfaxin provides 30 mg phospholipids (22.50 mg DPPC and 7.50 mg POPG, Na), 4.05 mg PA, and 0.862 mg sinapultide in tromethamine and sodium chloride. Glacial acetic acid is used to adjust the pH of the buffer to 7.4 (range 7.0 to 8.0). Surfaxin contains no preservatives.Â
Prescribed for To prevent respiratory distress syndrome (RDS) in premature infants at high risk for RDS. It reduces the incidence of RDS at 24 hours and mortality due to RDS.
Chemical Name N.A.
Formulation Intratracheal Suspension: 8.5 mL suspension in a glass vial. Each mL contains 30 mg phospholipids [22.50 mg dipalmitoylphosphatidylcholine (DPPC) and 7.50 mg palmitoyloleoyl-phosphatidylglycerol, sodium salt (POPG, Na)], 4.05 mg palmitic acid (PA), and 0.862 mg sinapultide.
Physcial Appearance Suspension
Route of Administration Intratracheal administration
Recommended Dosage The recommended dose of surfaxin is 5.8 mL per kg birth weight. Up to 4 doses of surfaxin can be administered in the first 48 hours of life. Doses should be given no more frequently than every 6 hours.
Contraindication None
Side Effects Administration-related oxygen desaturation and bradycardia
Useful Link http://www.drugbank.ca/drugs/DB04897
PubMed ID 17533176, 16740886, 16452346, 15833063, 15813666, 15805381, 12802703
3-D Structure Th1146 (View) or (Download)

Entry 2
(2) Primary information
ID 1642
ThPP ID Th1146
Therapeutic Peptide/Protein Name Lucinactant
Sequence KLLLLKLLLLKLLLLKLLLLK view full sequnce in fasta
Functional Classification Ib
Molecular Weight 2470.2
Chemical Formula C126H238N26O22
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description A new synthetic peptide containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). It specifically mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine,Â DPPCÂ and palmitoyloleoyl phosphatidylglycerol,POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.Â FDAÂ approved it on March 6, 2012.
Indication/Disease Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Pharmacodynamics Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.
Mechanism of Action Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
Toxicity Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.rxlist.com/surfaxin-drug/side-effects-interactions.htm
PubMed ID 17533176, 16740886, 16452346, 15833063, 15813666, 15805381, 12802703
3-D Structure Th1146 (View) or (Download)

Entry 3
(3) Primary information
ID 1643
ThPP ID Th1146
Therapeutic Peptide/Protein Name Lucinactant
Sequence KLLLLKLLLLKLLLLKLLLLK view full sequnce in fasta
Functional Classification Ib
Molecular Weight 2470.2
Chemical Formula C126H238N26O22
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description A new synthetic peptide containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). It specifically mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine,Â DPPCÂ and palmitoyloleoyl phosphatidylglycerol,POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.Â FDAÂ approved it on March 6, 2012.
Indication/Disease Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Pharmacodynamics Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.
Mechanism of Action Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
Toxicity Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories N.A.
Patents Number N.A.
Date of Issue N.A.
Date of Expiry N.A.
Drug Interaction N.A.
Target N.A.
Information of corresponding available drug in the market
Brand Name N.A.
Company N.A.
Brand Discription N.A.
Prescribed for N.A.
Chemical Name N.A.
Formulation N.A.
Physcial Appearance N.A.
Route of Administration N.A.
Recommended Dosage N.A.
Contraindication N.A.
Side Effects N.A.
Useful Link http://www.drugs.com/pro/surfaxin.html
PubMed ID 17533176, 16740886, 16452346, 15833063, 15813666, 15805381, 12802703
3-D Structure Th1146 (View) or (Download)

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1641
ThPP ID	Th1146
Therapeutic Peptide/Protein Name	Lucinactant
Sequence	KLLLLKLLLLKLLLLKLLLLK view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	2470.2
Chemical Formula	C126H238N26O22
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	A new synthetic peptide containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). It specifically mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine,Â DPPCÂ and palmitoyloleoyl phosphatidylglycerol,POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.Â FDAÂ approved it on March 6, 2012.
Indication/Disease	Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Pharmacodynamics	Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.
Mechanism of Action	Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
Toxicity	Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Pulmonary surfactants
Patents Number	US5407914
Date of Issue	03/06/12
Date of Expiry	11/07/13
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	Surfaxin
Company	Discovery Laboratories, Inc.
Brand Discription	ItÂ is a sterile, non-pyrogenic pulmonaryÂ surfactantÂ intended for intratracheal use only. It is a synthetic formulation consisting of phospholipids, aÂ fatty acid, and sinapultide (KL4peptide), a 21-amino acidÂ hydrophobic synthetic peptide. Surfaxin is a white to off-white opaque gel-like suspension at 2Â° to 8Â°C (36Â° to 46Â°F), which becomes a free-flowing suspension upon warming for 15 minutes in a dry block heater set at 44Â°C (111Â°F). Each mL of Surfaxin provides 30 mg phospholipids (22.50 mg DPPC and 7.50 mg POPG, Na), 4.05 mg PA, and 0.862 mg sinapultide in tromethamine and sodium chloride. Glacial acetic acid is used to adjust the pH of the buffer to 7.4 (range 7.0 to 8.0). Surfaxin contains no preservatives.Â
Prescribed for	To prevent respiratory distress syndrome (RDS) in premature infants at high risk for RDS. It reduces the incidence of RDS at 24 hours and mortality due to RDS.
Chemical Name	N.A.
Formulation	Intratracheal Suspension: 8.5 mL suspension in a glass vial. Each mL contains 30 mg phospholipids [22.50 mg dipalmitoylphosphatidylcholine (DPPC) and 7.50 mg palmitoyloleoyl-phosphatidylglycerol, sodium salt (POPG, Na)], 4.05 mg palmitic acid (PA), and 0.862 mg sinapultide.
Physcial Appearance	Suspension
Route of Administration	Intratracheal administration
Recommended Dosage	The recommended dose of surfaxin is 5.8 mL per kg birth weight. Up to 4 doses of surfaxin can be administered in the first 48 hours of life. Doses should be given no more frequently than every 6 hours.
Contraindication	None
Side Effects	Administration-related oxygen desaturation and bradycardia
Useful Link	http://www.drugbank.ca/drugs/DB04897
PubMed ID	17533176, 16740886, 16452346, 15833063, 15813666, 15805381, 12802703
3-D Structure	Th1146 (View) or (Download)

(2) Primary information
Entry 2
ID	1642
ThPP ID	Th1146
Therapeutic Peptide/Protein Name	Lucinactant
Sequence	KLLLLKLLLLKLLLLKLLLLK view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	2470.2
Chemical Formula	C126H238N26O22
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	A new synthetic peptide containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). It specifically mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine,Â DPPCÂ and palmitoyloleoyl phosphatidylglycerol,POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.Â FDAÂ approved it on March 6, 2012.
Indication/Disease	Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Pharmacodynamics	Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.
Mechanism of Action	Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
Toxicity	Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.rxlist.com/surfaxin-drug/side-effects-interactions.htm
PubMed ID	17533176, 16740886, 16452346, 15833063, 15813666, 15805381, 12802703
3-D Structure	Th1146 (View) or (Download)

(3) Primary information
Entry 3
ID	1643
ThPP ID	Th1146
Therapeutic Peptide/Protein Name	Lucinactant
Sequence	KLLLLKLLLLKLLLLKLLLLK view full sequnce in fasta
Functional Classification	Ib
Molecular Weight	2470.2
Chemical Formula	C126H238N26O22
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	A new synthetic peptide containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). It specifically mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine,Â DPPCÂ and palmitoyloleoyl phosphatidylglycerol,POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.Â FDAÂ approved it on March 6, 2012.
Indication/Disease	Intended for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.
Pharmacodynamics	Lucinactant is a new synthetic surfactant containing a protein that mimics human surfactant protein-B, is effective at preventing respiratory distress syndrome (RDS) and related complications in preterm infants. Lucinactant has been shown to have antiinflammatory properties, is resistant to proteolytic degradation and oxidation, and has no potential for transmitting animal-derived diseases. Lucinactant has proven safe and effective in the prevention of RDS in preterm infants and as a treatment for MAS in full-term infants and for adult ARDS.
Mechanism of Action	Pulmonary surfactant is a lipoprotein complex that is produced naturally in the lungs, where it lines the alveolar epithelium and serves to reduce surface tension, which facilitates alveoli expansion and allows gas exchange. Human surfactants contain phospholipids, predominantly dipalmitoylphosphatidylcholine (DPPC), in addition to surfactant proteins A, B, C and D. Surfactant is also a physical barrier to inhaled particle and noxious agents, enhances particle clearance, is involved in host defense against infection and possesses antiinflammatory properties. Several serious respiratory disorders have been associated with a loss or lack of endogenous surfactant. Lucinactant was designed to mimic the essential endogenous human surfactant protein B (SP-B).
Toxicity	Most common adverse reactions associated with the use of lucinactant are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	N.A.
Patents Number	N.A.
Date of Issue	N.A.
Date of Expiry	N.A.
Drug Interaction	N.A.
Target	N.A.
Information of corresponding available drug in the market
Brand Name	N.A.
Company	N.A.
Brand Discription	N.A.
Prescribed for	N.A.
Chemical Name	N.A.
Formulation	N.A.
Physcial Appearance	N.A.
Route of Administration	N.A.
Recommended Dosage	N.A.
Contraindication	N.A.
Side Effects	N.A.
Useful Link	http://www.drugs.com/pro/surfaxin.html
PubMed ID	17533176, 16740886, 16452346, 15833063, 15813666, 15805381, 12802703
3-D Structure	Th1146 (View) or (Download)